Kathryn Gutierrez
Family · El Paso, TXNPI 1851972632
Payments from drug & device makers
Across 484 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- AbbVie$1K
- Johnson & Johnson$1K
- Pfizer$873
- Takeda Pharmaceuticals U.S.A., Inc.$652
- Ardelyx, Inc.$520
- plus $2K from 17 others
What the payments were for
- Food & beverage$8,25997%
- Education$2913%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 108 | $1,492 |
| AbbVie | 86 | $1,488 |
| Johnson & Johnson | 60 | $1,223 |
| Pfizer | 55 | $873 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $652 |
| Ardelyx, Inc. | 22 | $520 |
| Phathom Pharmaceuticals, Inc. | 18 | $360 |
| Bristol Myers Squibb | 16 | $327 |
| Intercept Pharmaceuticals, Inc. | 18 | $299 |
| Ipsen Biopharmaceuticals, Inc | 13 | $244 |
| Madrigal Pharmaceuticals | 8 | $200 |
| Aimmune Therapeutics, Inc. | 16 | $198 |
| QOL Medical, LLC | 7 | $159 |
| Nestle Healthcare Nutrition Inc. | 6 | $99 |
| Lilly USA, LLC | 4 | $97 |
| E.r. Squibb & Sons, L.L.C. | 1 | $95 |
| Ferring Pharmaceuticals Inc. | 4 | $77 |
| Gilead | 3 | $49 |
| Redhill Biopharma Inc. | 1 | $24 |
| Celltrion USA Inc. | 1 | $23 |
| Novo Nordisk | 1 | $20 |
| Axonics, Inc. | 1 | $17 |
| Pharming Healthcare, Inc. | 1 | $15 |
How this compares
$8,549 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 29 | $106,945 |
| LinzessLinaclotide | 51 | $49,226 |
| VoqueznaVonoprazan Fumarate | 18 | $15,575 |
| Ursodiol | 61 | $12,570 |
| Dicyclomine Hcl | 292 | $9,668 |
| Dexlansoprazole DrDexlansoprazole | 22 | $8,764 |
| Mesalamine | 25 | $6,745 |
| Omeprazole | 391 | $6,739 |
| Famotidine | 330 | $5,694 |
| Esomeprazole Magnesium | 132 | $5,070 |
| Sucralfate | 38 | $3,614 |
| Pantoprazole Sodium | 196 | $2,733 |
| Lactulose | 19 | $1,225 |
| Clarithromycin | 22 | $846 |
| Lansoprazole | 19 | $649 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,492 | $106,94529 claims |
| AbbVieLinzess | $1,488 | $49,22651 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $360 | $15,57518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in El Paso
- Margarita FavelaEl Paso$73K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.